These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. New insights into the pathogenesis and treatment of chronic myeloproliferative disorders. Mesa RA Curr Opin Hematol; 2008 Mar; 15(2):121-6. PubMed ID: 18300758 [TBL] [Abstract][Full Text] [Related]
26. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Harrison C Br J Haematol; 2005 May; 129(3):293-306. PubMed ID: 15842653 [TBL] [Abstract][Full Text] [Related]
27. Myelodysplastic and myeloproliferative disorders in children. Hasle H Curr Opin Pediatr; 2007 Feb; 19(1):1-8. PubMed ID: 17224655 [TBL] [Abstract][Full Text] [Related]
28. Myelodysplasia and myeloproliferative disorders in childhood: an update. Emanuel PD Br J Haematol; 1999 Jun; 105(4):852-63. PubMed ID: 10554793 [No Abstract] [Full Text] [Related]
29. 11th Symposium on Molecular Biology of Hematopoiesis and Treatment of Myeloproliferative Diseases. Bormio, Italy, June 25-29, 1998. Abstracts. Acta Haematol; 1998; 100 Suppl 1():1-72. PubMed ID: 9725986 [No Abstract] [Full Text] [Related]
30. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). Murphy S Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227 [TBL] [Abstract][Full Text] [Related]
31. Haematologists specializing in the treatment of MPDs coordinated a combined effort with experts in other fields, in this case cardiology, dermatology and psychiatry. Introduction. Rønnov-Jessen D Hematol Oncol; 2009 Jun; 27 Suppl 1():1. PubMed ID: 19468980 [No Abstract] [Full Text] [Related]
32. European Working Group (EWG) meeting on myeloproliferative disorders (MPDDs). Brière J Pathol Biol (Paris); 2004 Jun; 52(5):265-6. PubMed ID: 15217711 [No Abstract] [Full Text] [Related]
33. [Use of interferon in patients with hairy cell leukemia and myeloproliferative disorders]. Skotnicki AB; Wolska-Smoleń T Acta Haematol Pol; 1994; 25(2 Suppl 1):124-35. PubMed ID: 8067197 [TBL] [Abstract][Full Text] [Related]
35. [Critical states in hemoblastoses (their typical forms and survival in a resuscitation department)]. Vorob'ev AI; Gorelov VG; Gorodetskiĭ VM; Shulutko EM Ter Arkh; 1993; 65(7):3-6. PubMed ID: 8211775 [No Abstract] [Full Text] [Related]
36. Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018. Heidel FH; Gale RP; Hochhaus A Leukemia; 2018 May; 32(5):1055-1056. PubMed ID: 29515237 [No Abstract] [Full Text] [Related]
37. A learning curve for laparoscopic splenectomy at an academic institution. Rege RV; Joehl RJ J Surg Res; 1999 Jan; 81(1):27-32. PubMed ID: 9889053 [TBL] [Abstract][Full Text] [Related]
38. [Interferon-alpha in the treatment of myeloproliferative syndromes]. Ballarino P; Castello G; Lerza R Recenti Prog Med; 1994 Nov; 85(11):546-50. PubMed ID: 7855389 [TBL] [Abstract][Full Text] [Related]
39. [Splenectomy in the treatment of hematologic diseases]. Popović M; Petrović M; Milovanović A; Matić S; Petrović M; Bosković D; Basić M Acta Chir Iugosl; 1997-1998; 44-45(1-1):37-42. PubMed ID: 10951812 [TBL] [Abstract][Full Text] [Related]